Article Text

other Versions

PDF
Phase 1 oncology trials and informed consent
  1. Franklin G Miller1,
  2. Steven Joffe2
  1. 1Department of Bioethics, National Institutes of Health, Bethesda, Maryland, USA
  2. 2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  1. Correspondence to Dr Franklin G Miller, Warren G. Magnuson Clinical Center, National Institutes of Health, Building 10, Room 1C118, Bethesda, MD 208921156, USA; fmiller{at}nih.gov

Abstract

Ethical concerns have been raised about the quality of informed consent by participants in phase 1 oncology trials. Interview surveys indicate that substantial proportions of trial participants do not understand the purpose of these trials—evaluating toxicity and dosing for subsequent efficacy studies—and overestimate the prospect of therapeutic benefit that they offer. In this article we argue that although these data suggest the desirability of enhancing the process of information disclosure and assessment of comprehension of the implications of study participation, they do not necessarily invalidate consent by phase 1 trial participants.

  • Informed Consent

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.